If the condition worsens after taking Sorafenib targeted drug, it is considered to be the reaction caused by the side effect of the targeted drug or the progression of the disease. Sorafenib belongs to the first-line new targeted drugs, which is commonly used in the treatment of inoperable renal cell carcinoma, inoperable or distant metastatic hepatocellular carcinoma, and can fully inhibit the growth of cancer cells without harming the healthy cells in the body. However, some patients who take Sorafenib targeted drugs instead of getting worse are usually considered to be the side effects of the targeted drugs, not really getting worse. Some patients may also experience disease progression after taking the drug due to poor sensitivity to the drug. If the condition worsens after taking sorafenib instead, it is commonly seen in liver cancer patients with severe liver function impairment, who cannot tolerate the side effects of the targeted drugs. It is recommended to consult the relevant departments in the hospital as soon as possible, check the liver function, stop using the drugs or reduce the dosage of the drugs under the guidance of the professional doctor, and consider switching to other targeted drugs if necessary.